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Abstract
Chalcones are promising synthons and bioactive scaffolds of great medicinal
interest due to their numerous pharmacological and biological activities. They are
well recognized to possess antimicrobial, anticancer, antitubercular, antioxidant,
anti-inflammatory, antileishmanial, and other significant biological activities. This
chapter highlights recent updates and applications of chalcones as biologically,
pharmacologically, and medicinally important entities.
Keywords: synthesis, characterization, PK/PD study
1. Introduction
Chalcones (trans-1,3-diaryl-2-propen-1-ones) (1) are α,β-unsaturated ketones
consisting of two aromatic rings (ring A and B) having diverse array of substituents.
Chalcone skeleton contains two aromatic rings linked by an aliphatic three-carbon
chain. The two rings of chalcone are interconnected by a highly electrophilic three-
carbon α,β-unsaturated carbonyl system that assumes linear or nearly planar struc-
ture. They possess conjugated double bonds and a completely delocalized π-electron
system on both the aromatic rings.
Chalcones, named so by Kostanecki and Tambor, are commonly known by
different names such as benzylideneacetophenone, phenyl styryl ketone, β-
phenylacrylophenone α-phenyl-β-benzoylethylene, etc. and constitute the central
core of biologically active heterocyclic compounds. Chalcones constitute good
synthons for a variety of novel heterocycles of high therapeutic potential and good
pharmaceutical profile [1, 2]. Chalcones themselves are identified as interesting
entities associated with several biological activities [3].
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The structural modifications of the chalcone rings have led to a high degree of
diversity that has proven useful for the development of new medicinal agents, and
thus chalcones have become an object of continued interest in both academia and
industry. The chalcones are well documented for a broad spectrum of biological
activities including antimicrobial, anticancer, cytotoxic, antioxidative, anti-
inflammatory, antiviral, and others [4]. Currently, chalcone derivatives have been
widely used for the treatment of viral disorders, cardiovascular diseases, stomach
cancer, food additives, and cosmetic formulation ingredients [5]. However, much
of the pharmacological potential of chalcones and their recent updates need to be
understood. The purpose of this chapter is to cover and describe the recent devel-
opments, preferably after 2015 to date, the utility of chalcones as medicinally
significant scaffolds, and their biological activities. It covers and highlights the
recent advances in the use of chalcones as antimicrobial, anticancer, antitubercular,
antioxidant, anti-inflammatory, and miscellaneous applications in biological and
medicinal fields.
2. Biological activities of chalcones
2.1 Antimicrobial chalcones
Antimicrobial agents are the drugs used to treat infectious diseases caused by
different types of bacteria and fungi. The use of these drugs is now common, and
continuous efforts are put by the scientific community to search for newer antimi-
crobial agents due to antimicrobial resistance (AMR) shown by the microbes.
Mutation, gene transfer, phenotypic change, and selective pressure are some of the
causes behind AMR [6]. Antimicrobial or drug resistance is commonly developed
by bacteria, fungi, parasites, and viruses when the microbe no longer responds to a
drug that previously treated them effectively. This AMR can lead to several issues
including difficulty in controlling the disease, a longer stay of the microbes in the
host, higher risks of spreading, and increase in mortality rates. Infectious diseases
are one of the common problems encountered globally. Although several commer-
cially marketed drugs are available, the search for new drug molecules becomes
essential for the treatment of infectious diseases [7]. Consequently, the search for
new antimicrobial agents becomes essential. Herein we discuss the recent updates in
the search of chalcones as an attempt to develop antimicrobial agents:
Methoxy-4’-amino chalcones (2) showed good in vitro antimicrobial activities
against Escherichia coli, Staphylococcus aureus, and Candida albicans. A molecular
docking study also supported the observed results showing good interactions with
the active sites of dihydropteroate synthase enzyme of E. coli and S. aureus [8].
The quinoxalinyl chalcones (3) synthesized by the Claisen-Schmidt condensa-
tion were found to be good antimicrobial agents. The antimicrobial studies were
carried out against Staphylococcus aureus, Escherichia coli, and Candida albicans using
the disk diffusion method. The selected chalcones were evaluated for anticancer and
cytotoxicity activity against MCF-7 cancer cell lines using the MTT assay method
showing good anticancer activity [9].
Some fluorinated chalcone-triazole hybrids (4) were studied for antimicrobial
activities against S. epidermidis, B. subtilis, E. coli, and P. aeruginosa bacterial and two
fungal strains, namely, A. niger and C. albicans, by standard serial dilution method
[10]. The results of the in vitro antimicrobial activity were compared with cipro-
floxacin and fluconazole standard drugs.
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Dehydroacetic acid chalcone-1,2,3-triazole hybrids (5) were shown to possess
good in vitro antimicrobial activities against Staphylococcus epidermidis, Bacillus
subtilis, Escherichia coli, and Pseudomonas aeruginosa bacteria and two fungal strains,
viz., Aspergillus niger and Candida albicans [11].
Thiazole-based chalcones including thiazolo[2,3-b]quinazoline and pyrido[4,3-d]
thiazolo[3,2-a]pyrimidine analogs (6 and 7) screened against both gram-positive and
gram-negative bacteria revealed that the tilted compounds had minimum inhibitory
concentration (MIC) values in the ranges of 1–4.0 μg/ml against S. aureus, B. subtilis,
M. luteus, E. coli, and P. aeruginosa [12]. The results were found to be comparable with
the ampicillin and ciprofloxacin standards.
Burmaoglu et al. reported antimicrobial activity of fluoro-substituted chalcones
(8) and (9) against S. aureus, S. pyogenes, E. faecalis, E. coli, and P. aeruginosa
bacteria and C. albicans, C. glabrata, and C. parapsilosis fungal strains. Some of the
tested compounds also exhibited antitubercular activity againstMycobacterium
tuberculosis [13].
Chalcones incorporated with a piperazine ring (10) exhibited promising antimi-
crobial activity against Escherichia coli, Aspergillus niger, Salmonella typhi, Penicil-
lium chrysogenum, and Staphylococcus aureus bacterial strains as well as Aspergillus
flavus, Bacillus subtilis, and Candida albicans fungi [14].
Talniya and Sood documented the synthesis and antibacterial activity of
chalcones (11) against Bacillus subtilis bacteria and Aspergillus niger fungi by disk
diffusion method [15]. The chalcones possessing o-chloro, p-chloro, and p-hydroxyl
substituents showed remarkable antimicrobial activity against the screened
microbes.
Oxazolidinones incorporated with chalcone hybrids (12) were evaluated for
in vitro antibacterial and antifungal activities by using the serial dilution method
[16]. Results showed moderate antimicrobial activities as compared with the stan-
dard drugs ciprofloxacin and linezolid.
Novel diarylsulfonylurea-chalcone hybrids (13) were evaluated by agar well
diffusion method against various strains of bacteria and fungi including Bacillus
subtilis, Escherichia coli, Bacillus pumilus, Staphylococcus aureus,Micrococcus luteus,
Candida albicans, and Penicillium chrysogenum. Most of the compounds showed
promising antibacterial and antifungal activity suggesting that the
diarylsulfonylurea-chalcone hybrids can be used for the treatment of diseases
caused by these microbial organisms [17].
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Vanillin moiety containing chalcones (14), (15), and (16)were synthesized by the
Claisen-Schmidt condensation of vanillin with different acetophenone derivatives
and were studied for antimicrobial activities by using agar disk diffusion and
microdilution methods [18]. The researchers found S. aureus and C. albicans to be the
most sensitive strains and E. faecalis to be the least sensitive against these chalcones.
The presence of halogens in chalcones increased their microbial susceptibility.
2.2 Anticancer chalcones
Cancer is a widely spreading disease all over the world, necessitating the need to
develop new anticancer agents [19]. Anticancer or antineoplastic drugs are those
that are effective in the treatment of malignant or cancerous disease. Increasing
recurrence of mammalian tumors and severe side effects of chemotherapeutic
agents reduce the clinical efficiency of a large variety of commonly used anticancer
agents, and thus, there is always a constant need to develop alternative or synergis-
tic anticancer drugs with minimal side effects [20].
The treatment of cancer is a complicated process as the drugs used target human
cells and albeit cells that have undergone genetic changes and are dividing at a fast
and uncontrolled rate. However, only a few anticancer drugs can differentiate
between normal tissue cells and cancer cells to a large extent. Thus, there is always a
constant need to develop alternative or synergistic anticancer drugs with minimal
side effects. This part of the present chapter highlights significant and recent
developments in chalcones used as anticancer agents:
Sulfonylpiperazines linked with [1,3]dioxolo[4,5-g]chromenones (17) were syn-
thesized by the aldol condensation and evaluated as antioxidants against DPPH,
ABTS, as well as antiproliferative agents against non-cancer MDCK cell lines [21].
The design, synthesis, and antitumor potential of chalcones (18) were studied
against human breast adenocarcinoma MCF-7 cells in a concentration-dependent
manner [22]. They triggered significant changes in cell morphology and biochemi-
cal/molecular parameters and revealed the apoptosis inductor nature of the titled
compounds and their application as promising alternatives for the treatment of
neoplasia, especially in terms of drug resistance development.
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Novel anthraquinone-chalcone hybrids (19) possessing amide functionality
were synthesized, then characterized, and reported for good cytotoxic potential
against K562, Jurkat, and HL-60 leukemia cell lines [23].
An apoptosis is an important phenomenon, which affects many diseases, such as
cancer and Alzheimer’s disease. Chalcones (20) induced apoptosis of human hepatic
and lung cancer cells and inhibited cancer cell migration and invasion [24].
The bis-chalcone derivatives (21) were studied for their ability to inhibit xan-
thine oxidase and growth inhibitory activity against MCF-7 and caco-2 human
cancer cell lines in vitro. The bis-chalcone with fluoro group at the 2nd or 2, 5th
position of B-ring was found to be a potent inhibitor of the enzyme possessing IC50
values in the low micromolar range. The activities of the compounds were found to
be around seven times higher than the standard allopurinol [25].
Chalcones (22)were synthesized and evaluated for anticancer activities on human
colorectal carcinoma cell line HCT116 by Dias et al. [26]. Halogens at the third position
of the chalconeswere found to enhance the anticancer activity of the titled compounds.
Leao et al. reported the chalcone derivatives (23) and (24) for cytotoxicity
against human tumor cells [27]. Some novel xanthine-chalcone hybrids (25) and
(26) were reported as promising anticancer agents [28].
A series of novel dithiocarbamate-chalcone derivatives (27) and (28)was designed,
synthesized, and evaluated for antiproliferative activity against three selected cancer
cell lines (EC-109, SK-N-SH, and MGC-803). Almost all the synthesized compounds
exhibited moderate to potent activity against all the tested cancer cell lines [29].
Pd(II) and Pt(II) complexes of chalcones (29) were studied for in vitro antimi-
crobial and antitumor activities against different microorganisms and the human
hepatocellular carcinoma cells indicating their use as promising antimicrobial
agents and anticancer drug candidates [30].
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Some novel Pt(IV) complexes of chalcone analogs (30) were synthesized and
evaluated for antiproliferative activity by using MTT assay. The in vitro evaluation
revealed that all Pt(IV) complexes showed good activity against the three human
cancer cells [31].
The overexpression of the CYP1 class of enzymes is associated with the devel-
opment of human carcinomas. The pyridine-4-yl series of chalcones (31) were
synthesized and screened for the inhibition of CYP1 isoforms in Sacchrosomes TM
and live human HEK293 cells. The chalcones bearing tri-alkoxy groups on non-
heterocyclic ring displayed selective inhibition of the CYP1A1 enzyme with IC50
values less than 70 nM [32].
The pyrazolic chalcone analogous compounds (32) were synthesized and evalu-
ated as potential chemotherapeutic agents for the treatment of hepatocellular carci-
noma [33]. Some of the screened compounds exhibited potent cytotoxic activity
against all the cancer cell lines tested and had good cytotoxic activities.
DNA ligases play a crucial role in causing cancer. Gupta et al. reported the
inhibition DNA ligases resulting in DNA nick-sealing activity followed by the
antiproliferative activity of the indole-chalcone based benzopyran chalcones (33)
on cancer cells [34].
Indolizine-chalcone hybrids (34) were synthesized and studied for apoptosis
and anticancer effect on human lymphoma cells by S. Park and coworkers [35].
Prenyl and geranyl group-bearing chalcones (35) were synthesized by using
regioselective iodination followed by the Suzuki coupling reaction and studied for
in vitro anticancer activity against human tumor cell line K562 by MTT assay.
Morphology changes revealed that the chalcone derivatives inhibited the prolifera-
tion of K562 cells by inducing apoptosis [36].
Leukemia is a hematologic malignancy with poor prognosis in humans.
Diprenylated chalcone (36) was studied as a new potential antileukemia agent [37].
Chalcones (37)were studied for antiproliferative activities against the human
TRAIL-resistant breast (MCF-7,MDA-MB-231), cervical (HeLa), ovarian (Caov-3),
lung (A549), liver (HepG2), colorectal (HT-29), nasopharyngeal (CNE-1), erythromye-
loblastoid (K-562), and T-lymphoblastoid (CEM-SS) cancer cells byMai [38].
Triazole incorporated with chalcones (38) and (39) was synthesized and evalu-
ated for 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
cytotoxicity assay against a series of four human cancer cell lines (MCF-7, MIA-Pa-
Ca-2, A549, HepG2) [39].
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2.3 Antitubercular chalcones
Tuberculosis (TB), caused by the acid-fast gram-positive bacillus,Mycobacte-
rium tuberculosis, remains the leading source of bacterial infectious disease [40].
M. tuberculosis establishes an infection through an invasion of alveolar macrophages.
TheMycobacterium tuberculosis encodes for more than 60 adenylating enzymes,
mainly tRNA synthetases, acyl-AMP ligases, etc. [41]. Currently, the treatment of TB
employs four first-line drugs, isoniazid, rifampin, pyrazinamide, and ethambutol,
which must be administered in the body daily for a 2-month intensive phase.
However, for susceptible TB strains, this therapy is 95% effective. The emergence of
multidrug-resistant (MDR) strains, defined as resistant to isoniazid and rifampin,
requires the use of less effective and more toxic second-line TB drugs. Herein we
discuss some recent updates in the application of chalcones against tuberculosis:
New sulfonamide-bearing chalcones (40)were synthesized by the Claisen-Schmidt
condensation and were reported as excellent antituberculosis hits showing low selec-
tivity, being equally inhibitory toM. tuberculosis and mammalian T3T cells [42].
Gomes et al. studied antitubercular activities of chalcones (41) and (42). The
chalcones showed good selectivity towards M. tuberculosis with low cytotoxicity
against Vero cells and thus possess promising antitubercular potential [43].
Spirochromone annulated chalcone conjugates (43) were documented for
antitubercular activity againstMycobacterium tuberculosis H37Rv strain. Molecular
docking studies performed against the receptors revealed MTB phosphotyrosine
phosphatase B protein as the most probable target based on the high binding-
affinity scores [44].
Babu et al. studied chalcones containing nitrophenyl moieties (44) for
antitubercular activity using MABA assay and antibacterial and antifungal activities
by cup plate method. Molecular docking study predicted the inhibition of thymi-
dine kinase of theMycobacterium tuberculosis [45].
7
Biological Role of Chalcones in Medicinal Chemistry
DOI: http://dx.doi.org/10.5772/intechopen.91626
2.4 Antioxidant chalcones
Antioxidants are the compounds that inhibit the oxidation process. These sub-
stances can prevent or slow damage to cells caused by free radicals. Oxidation is a
chemical reaction that generates free radicals, thereby leading to chain reactions
which may damage the cells of organisms and hence responsible for oxidative stress
resulting in chronic diseases such as heart diseases, stroke, cancer, arthritis, respi-
ratory diseases, Parkinson’s disease, and other inflammatory conditions [46].
Cao et al. documented a series of 40-OH-flurbiprofen-chalcone hybrids (45) and
evaluated them as potential multifunctional agents for the treatment of Alzheimer’s
disease. Besides, the compounds were reported for good antioxidant activities,
MAO inhibitions, biometal chelating abilities, and in vitro anti-neuroinflammatory
activities [47].
Selenoenzymes and nuclear factor erythroid 2-related factor 2 (Nrf2)-regulated
phase II enzymes constitute the main components of cellular redox and antioxidant
systems giving information about multiple interrelations involved in the oxidation
processes. Chalcones (46) were proved to interfere with the biosynthesis of Nrf2-
regulated selenoenzymes [48].
El-Sayed et al. documented the antioxidant activity of chalcones (47) [49].
The chalcone derivatives (48) were synthesized by the Claisen-Schmidt con-
densation with KOH in ethanol at room temperature under sonication conditions
and screened for antioxidant potential by Polo et al. [50].
The chalcones (49) were studied as potent antioxidants by Tajammal and
coworkers. These compounds have lower IC50 values than the Trolox and ascorbic
acid standards [51].
A series of chalcone (50) analogs were designed, synthesized, and screened for
antioxidant activities. The chalcone was found as a promising anti-ischemic stroke
drug candidate, providing novel dual-antioxidant mechanism strategies and con-
cepts for oxidative stress-related disease treatment [52].
The prenylated chalcones (51) were reported for good antioxidant activity [53].
2.5 Anti-inflammatory chalcones
Anti-inflammatory drugs are the drugs which are used to reduce pain and
inflammation. In other words, these are pain-relieving drugs. These drugs work
mainly by inhibiting the cyclooxygenase enzymes, COX-1 and COX-2, that produce
prostaglandins [54]. Herein we discuss some of the efforts for the development of
chalcone-based heterocycles as effective anti-inflammatory compounds:
8
Vector-Borne Diseases - Recent Developments in Epidemiology and Control
Indole-based chalcones (52) were synthesized and evaluated for in vitro COX-1
and COX-2 inhibitory activity [55].
α-Substituted 20,3,4,40-tetramethoxychalcones (53) and (54) were evaluated for
their ability to modulate inflammatory responses to influence on heme oxygenase-1,
nitric oxide synthase, and cytokine expression levels. Anti-inflammatory
activity was correlated with thiol-alkylating activity, i.e., stronger electrophiles
substituted with CF3, Br, and Cl were found to be more potent than the remaining
derivatives [56].
Zhang et al. identified methoxy chalcones (55) as a potential candidate for
treating acute inflammatory diseases [57].
Pyrazole- and morpholine-containing chalcones (56) were reported for anti-
inflammatory activity by Gadhave and Uphade. The anti-inflammatory activity
performed by carrageenan-induced rat paw edema method showed good potency of
some of the tested compounds as compared with the standard diclofenac drug [58].
Nurkenov et al. studied the in vitro anti-inflammatory effect of chalcones (57)
to inhibit the lipopolysaccharide-induced production of anti-inflammatory cytokine
interleukin-6 and tumor necrosis factor [59].
The imidazole containing chalcone molecule (58) demonstrated noteworthy
anti-inflammatory activity as compared with the standard drug, indomethacin [60].
1-[3-Methoxy-4-(5-nitro-furan-2-ylmethoxy)-phenyl]-3-(substituted phenyl)-
propenones (59) synthesized by the condensation of furfural and apocynin were
evaluated for anti-inflammatory activity [61].
2.6 Miscellaneous applications of chalcones
Besides the above-discussed applications, chalcones are useful for miscellaneous
applications. Some of them are mentioned as follows:
Leishmania is a genus of trypanosomes responsible for the disease leishmaniasis.
Leishmaniasis is spread through sand flies of the genus Phlebotomus, primary hosts
being the vertebrates. The chalcone (60) was evaluated against 29 promastigotes of
Leishmania donovani exhibiting low toxicity against mammalian cells [62].
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A series of new chalcone-rivastigmine hybrids (61) was designed, synthesized,
and evaluated in vitro for the ability to inhibit human acetylcholinesterase and
butyrylcholinesterase. Results showed that these compounds exhibited selective
activity in micro- and submicromolar ranges as compared with the standard
rivastigmine and thus the compounds can serve as the lead ones for the treatment of
Alzheimer’s disease [63].
Sang et al. reported AChE/BChE inhibitory, MAO-A/MAO-B inhibitory, and
antioxidant activities of chalcone-O-carbamate derivatives (62). Results revealed
that the compounds show highly selective BChE inhibitory activity with IC50 values
of 1–3 mM range [64].
Some 1,3,4-oxadiazole/thiadiazole-chalcone conjugates (63) were synthesized
and evaluated for in vitro and in vivo antiviral activities against TMV. These conju-
gates have low binding constant values which were comparable to the standard
ningnanmycin [65].
Amide tethered 7-chloroquinoline-chalcone bifunctional hybrids (64) were syn-
thesized and employed as antimalarial agents against the resistant strain of Plasmo-
dium falciparum. Methoxy substituent at the para position of ring B on chalcones
and longer alkyl chain lengths significantly improved the antiplasmodial profiles of
the chalcone derivatives [66].
The halogenated 1-tetralone or 6-amino-1-tetralone chalcone derivatives (65)
were synthesized and evaluated for inhibitory effects against ROS production in
LPS-stimulated RAW 264.7 macrophages. The structure-activity relationship
revealed that amino moiety at the sixth position of 1-tetralone chalcones plays an
important role for greater ROS inhibitory potency [67].
Chalcone derivatives (66) were studied for hepatoprotective ability, and the
results were compared with the standard hepatoprotective drug silymarin. The
experimental results were supported by a molecular docking study [68].
Triazole-linked 4-aminoquinoline-chalcone/-N-acetylpyrazoline conjugates
(67) were synthesized and evaluated for antiplasmodial activities against cultured
chloroquine-resistant strain. The activities were found to be dependent on the
length of the alkyl chain as well as on the presence of methoxy substituents on the
chalcone rings [69].
Chalcone analogs (68) were synthesized and evaluated for cytotoxic effects in
human hepatoma HepG2 cells. The percentage of apoptotic cells was significantly
higher in the compounds than that in the control cells [70].
The oxygenated chalcones (69) were found to inhibit monoamine oxidases, and
the lead compounds were found to be nontoxic at 200 μg/mL in normal rat spleen
cells [71].
Hameed et al. studied the quinoline-based chalcone compounds (70) as reverse
transcriptase inhibitors. Bromo- and chloro-substituted chalcones exhibited a high
degree of inhibition against the reverse transcriptase [72].
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Histoplasmosis is a fungal infection caused by the dimorphic fungus Histoplasma
27 capsulatum. Hydroxyl group-bearing chalcones (71) and (72) were studied for
histoplasmosis by Wanessa et al. [73].
Sashidhara et al. documented the antiulcer activity of some novel quinoline-
chalcone hybrids (73) in various ulcer models in Sprague Dawley rats. Additional
studies including in vitro metabolic stability and in vivo pharmacokinetics showed
their potential to act as an orally active and safe candidate for the development of an
antiulcer agent [74].
Pyrene ring-bearing chalcone (74)was studied as a sensitive and highly selective
sensor for the detection of aluminum (Al3+) ions by fluorimetric studies by Suresh et al.
The chalcone was found to be useful for the electrosorptive removal of Al3+ ion and
several other biological applications including the bio-imaging of bacterial cells [75].
Chalcones (75) were reported for potent antimalarial activities against Plasmo-
dium falciparum using Rieckmann’s method. Allyloxy, hydroxy, and alkoxy func-
tional groups increased the antimalarial activity of the chalcone derivatives [76].
Human African trypanosomiasis is an infectious disease that affects the lives of
people living in rural areas of Africa. Beteck et al. studied the antitrypanosomal activ-
ities of indanone-based chalcone analogs (76) by screening against T.b. brucei [77].
3. Conclusion
Chalcones and their analogs possess significant biological activities including
antimicrobial, anticancer, antitubercular, antioxidant, anti-inflammatory,
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antileishmanial, enzyme inhibitory, and miscellaneous applications and hence
acquire a unique place in medicinal chemistry. The growing interest of synthetic
organic, pharmacological, and medicinal chemists towards chalcones and their
derivatives will be continued in the future also. This chapter is expected to provide a
stimulus for researchers to design, synthesize, and carry out further investigation
on the pharmacological effects of new chalcone derivatives for different biological
activities.
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